Biocryst Pharmaceuticals (BCRX) Cash from Operations (2010 - 2026)

Biocryst Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 61791000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 124.56% year-over-year to 61791000.0; the trailing twelve-month figure through Mar 2026 stood at 313095000.0 (up 1311.06% YoY), and the FY2025 full-year result was 347369000.0, up 767.76% from the prior year.
• Cash from Operations for Q1 2026 stood at 61791000.0, down from 291960000.0 in the prior quarter.
• The five-year high for Cash from Operations was 291960000.0 in Q4 2025, with the low at 77800000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 1378411.76 across 5 years, with a median of 19897000.0 in 2023.
• Annual changes were most pronounced in 2025 — Cash from Operations soared 5700.61% — and 2026, when it slumped 124.56%.
• Biocryst Pharmaceuticals' Cash from Operations stood at 23849000.0 in 2022, then soared by 62.61% to 8918000.0 in 2023, then jumped by 41.55% to 5213000.0 in 2024, then soared by 5700.61% to 291960000.0 in 2025, then plunged by 121.16% to 61791000.0 in 2026.
• The last three Cash from Operations figures came in at 61791000.0 (Q1 2026), 291960000.0 (Q4 2025), and 41624000.0 (Q3 2025), per Business Quant data.